FDA sets date to review Affymax anemia drug - BusinessWeek PDF Print
BusinessWeek
Affymax is seeking approval to market the drug to adult patients on kidney dialysis, who typically suffer from anemia, a blood disorder that causes dizziness and weakness. Peginesatide is part of a class of drugs known as erythropoiesis stimulating

...

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.

Notice: Undefined variable: query in /home/globaldi/public_html/components/com_joomlawatch/class.joomlawatch.db.php on line 129